Innovations save lives
In the last quarter of 2010, PATH interventions reached unprecedented success—helping protect both children and adults from a range of health problems from HIV to malnutrition.
Protection from cervical cancer
PATH and our partners complete vaccination of 57,000 girls in India, Peru, Uganda, and Vietnam against HPV, the primary cause of cervical cancer. The six-year project is building evidence on the most effective strategies for delivering the vaccine.
Partnerships for vaccines against pneumonia
Over the course of the year, PATH establishes four new research collaborations to support the development of ten pneumococcal vaccines reflecting five scientific strategies. The partnerships aim to develop vaccines that protect against the types of pneumococcus affecting the developing world—at a price low-income countries can afford.
Strengthening health information systems
PATH and our partners develop methods that help countries determine user and system requirements for health information systems. Beginning with a set of common requirements for computerized logistics management information systems, the team helps Zambia’s Ministry of Health establish a road map to improve the country’s supply chain system.
Hope for an end to epidemic meningitis
The people of Burkina Faso gather to receive a new vaccine that could end epidemics of meningococcal A meningitis, which in the last century has killed or disabled hundreds of thousands in sub-Saharan Africa. The new vaccine, called MenAfriVac™, is the culmination of nearly a decade of work by the Meningitis Vaccine Project (MVP), a partnership between PATH and WHO. MVP and its many collaborators developed and introduced a vaccine that provides long-lasting protection, can be used preventively, and—at less than US$0.50 a dose—was developed with affordability for African countries in mind.
In just one month, nearly 20 million people in Burkina Faso, Mali, and Niger receive the vaccine. In the next few years, PATH and WHO plan to bring MenAfriVac to as many as 315 million more children and young adults in Africa. WHO estimates that, if enough people receive the vaccine, MenAfriVac will save nearly 150,000 lives.
Photos: PATH/Amynah Janmohamed, PATH/David Lubinski, PATH/Gabe Bienczycki.